The current study deals with the evaluation of the impacts of novel immunotherapy agents checkpoint inhibitors on human melanoma cell population growth and survival. MTT assay was used to demonstrate the ability of pembrolizumab, nivolumab, and ipilimumab to reduce viable cell numbers, reducing such numbers by 31-37% compared to untreated control. Vemurafenib and dabrafenib also suppress viability, but only slightly (13-16% decrease). The intraleukocytic tyrosine kinase inhibitors, imatinib and dasatinib, were less toxic and showed a 20-24% viability reduction. Parallel to this, the cell proliferation assay showed the highest decrease in cytokine production by pembrolizumab and nivolumab (28-38%), while the tyrosine kinase and RAF inhibitors exhibited smaller anti-proliferative effects. Our investigation demonstrated that the most effective checkpoint inhibitors, including especially the PD-1 inhibitors pembrolizumab and nivolumab, were those exerting significant anti-tumor activities against human melanoma cells by causing cytotoxicity and inhibiting proliferation. The narrower approaches were less effective in general in comparison to broader ones. In-depth research on regulatory pathways and synergistic drug management is needed as well.